Late in the day on Friday, September 20, 2019, Genentech informed NHF and HFA that a contracted specialty pharmacy, Medvantx, had shipped incorrect length injection needles to patients who receive Hemlibra through the Genentech Patient Foundation. NHF and HFA posted that notice on September 21st. Today we followed up with a letter to Genentech and Medvantx asking a number of questions about how this error occurred; about Genentech’s notification of affected patients; and about potential consequences for affected patients.
This is an ongoing discussion and NHF and HFA will update the bleeding disorders community as further information develops.
Please note that NHF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. If you have any questions or concerns about your medical treatment, please consult your physician.